Terpenoids: opportunities for biosynthesis of natural product drugs using engineered microorganisms.
Terpenoids represent a diverse class of molecules that provide a wealth of opportunities to address many human health and societal issues. The expansive array of structures and functionalities that have been evolved in nature provide an excellent pool of molecules for use in human therapeutics. While this class of molecules has members with therapeutic properties including anticancer, antiparasitic, antimicrobial, antiallergenic, antispasmodic, antihyperglycemic, anti-inflammatory, and immunomodulatory properties, supply limitations prevent the large scale use of some molecules. Many of these molecules are only found in ppm levels in nature thus requiring massive harvesting to obtain sufficient amounts of the drug. Synthetic biology and metabolic engineering provide innovative approaches to increase the production of the desired molecule in the native organism, and most importantly, transfer the biosynthetic pathways to other hosts. Microbial systems are well studied, and genetic manipulations allow the optimization of microbial metabolisms for the production of common terpenoid precursors. Using a host of tools, unprecedented advancements in the large scale production of terpenoids have been achieved in recent years. Identification of limiting steps and pathway regulation, coupled with design strategies to minimize terpenoid byproducts wih a high flux to the desired biosynthetic pathways, have yielded greater than 100-fold improvements in the production of a range of terpenoids. This review focuses on the biodiversity of terpenoids, the biosynthetic pathways involved, and engineering efforts to maximize the production through these pathways.
Ajikumar
Parayil Kumaran
PK
Department of Chemical Engineering, Room 56-469, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Tyo
Keith
K
Carlsen
Simon
S
Mucha
Oliver
O
Phon
Too Heng
TH
Stephanopoulos
Gregory
G
D000890:Anti-Infective Agents / Q000378:metabolism; D000893:Anti-Inflammatory Agents / Q000378:metabolism; D000970:Antineoplastic Agents / Q000378:metabolism; D001419:Bacteria / Q000378:metabolism*; D001688:Biological Products / Q000096:biosynthesis*; D005818:Genetic Engineering; D013729:Terpenes / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D001688:Biological Products; D013729:Terpenes